81,95 €
81,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
41 °P sammeln
81,95 €
81,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
41 °P sammeln
Als Download kaufen
81,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
41 °P sammeln
Jetzt verschenken
81,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
41 °P sammeln
  • Format: PDF

This book discusses the latest findings on the pathogenesis and treatment of IgA nephropathy. It particularly focuses on recently recognized initiation and progression factors and the varying treatment strategies in different regions, such as Asia, Europe, and the United States. More than 40 years have passed since Dr. Jean Berger first described primary IgA nephropathy ("Nephropathy with mesangial IgA-IgG deposits") as a new disease entity.
Immunohistopathologically, IgA nephropathy is characterized by the granular deposition of IgA (IgA1) and C3 in the glomerular mesangial areas with
…mehr

Produktbeschreibung
This book discusses the latest findings on the pathogenesis and treatment of IgA nephropathy. It particularly focuses on recently recognized initiation and progression factors and the varying treatment strategies in different regions, such as Asia, Europe, and the United States. More than 40 years have passed since Dr. Jean Berger first described primary IgA nephropathy ("Nephropathy with mesangial IgA-IgG deposits") as a new disease entity.

Immunohistopathologically, IgA nephropathy is characterized by the granular deposition of IgA (IgA1) and C3 in the glomerular mesangial areas with mesangial cell proliferation and the expansion of mesangial matrices. It is clear that IgA nephropathy is one of the most common types of chronic glomerulonephritis in the world. This disease may lead to end-stage kidney disease, with its enormous economic impact on healthcare everywhere. Efforts by many investigators around the world have gradually clarified various aspects of the pathogenesis and treatment of IgA nephropathy. However, there are many controversial strategies for the treatment of patients with IgA nephropathy throughout the world, as there are several limitations for treatment in each country. This volume provides nephrologists everywhere with an overview and comparison of both global and regional findings in basic and clinical fields in IgA nephropathy. It covers genetic variation, aberrant IgA1 production, and classification etiology, guidelines, and treatment goals, with all chapters written by top international researchers.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Editor: Dr. Yasuhiko Tomino Division of Nephropathy, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan (Present address: Medical Corporation SHOWAKAI, Tokyo, Japan)
Rezensionen
"This is an informative look at IgA nephropathy, one of the most common types of chronic glomerulonephritis in the world. ... This is a resource for those engaged in research or clinical care of patients with IgA nephropathy. It is likely most appropriate for nephrology trainees and those who practice general nephrology, as well as researchers in the field. ... Each chapter is divided into sections, clearly demarcated by objectives, and includes colorful images and figures." (Jon Webb, Doody's Book Reviews, February, 2017)